Non-small-cell Lung Cancer With Somatic EGFR Mutations Terminated Phase 2 Trials for Afatinib (DB08916)

IndicationStatusPhase
DBCOND0075976 (Non-small-cell Lung Cancer With Somatic EGFR Mutations)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02488694Maintaining ERBB Blockade in EGFR-mutated Lung CancerTreatment